{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:24:21Z","timestamp":1792610661064,"version":"4.5.0"},"reference-count":88,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2024,5,3]]},"DOI":"10.1080\/13543776.2024.2365411","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:30:53Z","timestamp":1717669853000},"page":"365-382","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["PIM kinase inhibitors: an updated patent review (2016-present)"],"prefix":"10.1080","volume":"34","author":[{"given":"Anushka","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Asati","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debarshi Kar","family":"Mahapatra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanmati Kumar","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bharti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21284"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26273"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.15430\/JCP.2018.23.3.109"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1996.00001.x"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-04-0192"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2021.129995"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10165-3"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0095-z"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-021-00656-3"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209058"},{"key":"e_1_3_4_13_1","volume-title":"Targeting eIF4F Translation Initiation Complex in order to sensitize blood malignancies to targeted agents","author":"Herzog LO","year":"2020","unstructured":"Herzog LO. Targeting eIF4F Translation Initiation Complex in order to sensitize blood malignancies to targeted agents. Irvine: University of California; 2020."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01966.x"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.20052"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034736"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054746"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014266"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013214108"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2986"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117866"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027227"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210823"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.4142\/jvs.2001.2.3.167"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210791033914"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107454"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2009.06.008"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom8010007"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2020.11.011"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01802"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21409"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm3009234"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9110735"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16320"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.69"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06476.x"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210794454996"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2015.561"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200522094"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.03.050"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.13172"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0535"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520618666180131113519"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.06.044"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017079"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0049-8"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0663"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.lawsocsci.3.081806.112900"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.21"},{"key":"e_1_3_4_50_1","first-page":"197","article-title":"Intellectual property and the politics of emerging technology: Inventors, citizens, and powers to shape the future","volume":"84","author":"Hilgartner S","year":"2009","unstructured":"Hilgartner S. Intellectual property and the politics of emerging technology: Inventors, citizens, and powers to shape the future. Chi Kent L Rev. 2009;84:197.","journal-title":"Chi Kent L Rev"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/0126839-200809060-00005"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114739"},{"key":"e_1_3_4_53_1","unstructured":"Mark JB Brandon C Jingyi L. Inventor; Snap Bio Inc. assignee. PIM kinase inhibitor compositions methods and uses thereof. WO2019090205A1. 2022."},{"key":"e_1_3_4_54_1","unstructured":"Li YL Burns DM Feng H et al. Inventor; Incyte Holdings Corp assignee. Bicyclic aromatic carboxamide compounds useful as PIM kinase inhibitors. CA2897200C. 2021."},{"key":"e_1_3_4_55_1","unstructured":"Fern\u00e1ndez P Escobar RMA Fagundo RCR et al. Inventor; Fundaci\u00f3n Centro Nacional de Investigaciones Oncol\u00f3gicas Carlos III assignee. Macrocyclic compounds as protein kinase inhibitors. EP2710018B1. 2021."},{"key":"e_1_3_4_56_1","unstructured":"Li YL Yao W Combs AP et al. Inventor; Incyte Holdings Corp assignee. Heterocyclylamines as PI3K inhibitors. EP3513793B. 2021."},{"key":"e_1_3_4_57_1","unstructured":"Weihui CAI Yuanwei Z Fang J. Inventor; Shenzhen Haiban Pharmaceutical Co. Ltd. assignee. Pyrimidine compound chloride salt thereof and manufacturing and application of same. US11066401B2. 2021."},{"key":"e_1_3_4_58_1","unstructured":"Blackaby W Burch J Hodges AJ et al. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. EP2900657B1. 2020."},{"key":"e_1_3_4_59_1","unstructured":"Xu Y Brenning BG Kultgen SG. Inventor; Sumitomo Dainippon Pharma Oncology Inc. assignee. Substituted imidazo[1 2-B]pyridazines as protein kinase inhibitors. US10875864B2. 2020."},{"key":"e_1_3_4_60_1","unstructured":"Blackaby W Burch J Hodges AJ et al. Inventor. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use thereof. EA031622B1. 2019."},{"key":"e_1_3_4_61_1","unstructured":"Bae IH Son JB Han SM et al. Inventor; Hanmi Pharm. Co. Ltd. assignee. Thieno[3 2-d]pyrimidine derivatives having inhibitory activity for protein kinases. EP2797927B1.2019."},{"key":"e_1_3_4_62_1","unstructured":"Burch J Chen H Wang X et al. Inventor; F. Hoffmann-La Roche AG assignee. Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. EP3119775B1. 2019."},{"key":"e_1_3_4_63_1","unstructured":"Vechorkin O Li YL Sokolsky A et al. Inventor; Incyte Corporation assignee. Heterocyclic compounds useful as PIM kinase inhibitors. US10450296B2. 2019."},{"key":"e_1_3_4_64_1","unstructured":"Fernandez JP Aparicio CB Hergueta AR et al. Inventor; assignee. Tricyclic compounds for use as kinase inhibitors. CA2786002C. 2018."},{"key":"e_1_3_4_65_1","unstructured":"Xu Y Brenning BG Kultgen SG et al. Inventor; tolero pharmaceuticals inc. assignee. heterocyclic protein kinase inhibitors. EP2734205B1. 2018."},{"key":"e_1_3_4_66_1","unstructured":"Vechorkin O Li YL Sokolsky A et al. Inventor; Incyte Corporation assignee. Heterocyclic compounds useful as PIM kinase inhibitors. US9920032B2. 2018."},{"key":"e_1_3_4_67_1","unstructured":"Casuscelli F Piutti C Ermoli A et al. Inventor; Nerviano Medical Sciences Srl assignee. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors. EP2614065B1. 2017."},{"key":"e_1_3_4_68_1","unstructured":"Ge Y Inventor; Jikai Biosciences Inc. assignee. PIM kinase inhibitors and preparation method and use in medicinal manufacture thereof. EP2743271B1. 2017."},{"key":"e_1_3_4_69_1","unstructured":"Casuscelli F Casale E Montemartini M et al. Inventor; Nerviano Medical Sciences S.R.l. assignee. Substituted 3 4-dihydropyrrolo[1 2-a]pyrazin-1(2h)-one derivatives as kinase inhibitors. EP2788351B1. 2017."},{"key":"e_1_3_4_70_1","unstructured":"Vechorkin O Feng H Li YL et al. Inventor; Incyte Corporation assignee. Pyridineamine compounds useful as PIM kinase inhibitors. US9540347B2. 2017."},{"key":"e_1_3_4_71_1","unstructured":"Burger M Lindvall M Han W et al. Inventor. PIM kinase inhibitors and methods of their use. 2016."},{"key":"e_1_3_4_72_1","unstructured":"Wang X. Inventor; F. Hoffmann-La Roche AG assignee. Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. EP2556066B1. 2016."},{"key":"e_1_3_4_73_1","unstructured":"Do S Hu H Kolesnikov A et al. Inventor; Genentech Inc. assignee. Pyrazolo[3 4-c]pyridine compounds and methods of use. US9260425B2.2016."},{"key":"e_1_3_4_74_1","unstructured":"Haddach M Tran JA Pierre F et al. Inventor; Senhwa Biosciences Inc. assignee. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors. US9303033B2. 2016."},{"key":"e_1_3_4_75_1","unstructured":"Burch J Sun M Wang X et al. Inventor; Genentech Inc. assignee. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US9328106B2. 2016."},{"key":"e_1_3_4_76_1","unstructured":"Bieberich CJ Li X. Inventor; University of Maryland assignee. PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers. US20200230125A1. 2022."},{"key":"e_1_3_4_77_1","unstructured":"Bieberich CJ Li X Joglekar T. Inventor; University of Maryland assignee. PIM kinase inhibitors in combination with RNA splicing modulators\/inhibitors for treatment of cancers. US20200046689A1. 2020."},{"key":"e_1_3_4_78_1","unstructured":"Vechorkin O Li YL Sokolsky A et al. Inventor; Incyte Corporation assignee. Heterocyclic compounds useful as PIM kinase inhibitors. US20170096411A1. 2018."},{"key":"e_1_3_4_79_1","unstructured":"Lee J Kim S Chu H et al. Inventor. Novel PIM Kinase Inhibitor and Uses Thereof. KR20210108684A. 2021."},{"key":"e_1_3_4_80_1","unstructured":"Xu Y Brenning BG Steven G et al. Inventor; Sumitomo Dainippon Pharma Oncology Inc. assignee. Substituted imidazo[1 2-b]pyridazines as protein kinase inhibitors. US20200102313A1. 2020."},{"key":"e_1_3_4_81_1","unstructured":"Vechorkin O Feng H Li YL et al. Inventor; Incyte Corporation assignee. Pyridineamine compounds useful as PIM kinase inhibitors. US20160347735A1. 2017."},{"key":"e_1_3_4_82_1","article-title":"Inventor; Shanghai Jikai Medical Technology Co. Ltd. assignee. Pyridine derivate PIM kinase inhibitor and preparation method thereof and the application in pharmacy","author":"Yu GE","year":"2019","unstructured":"Yu GE. Inventor; Shanghai Jikai Medical Technology Co. Ltd. assignee. Pyridine derivate PIM kinase inhibitor and preparation method thereof and the application in pharmacy. CN105218523A. 2019.","journal-title":"CN105218523A"},{"key":"e_1_3_4_83_1","unstructured":"Weihui CAI Yuanwei Z Fang J. Inventor; Shenzhen Haibin Pharmaceutical Co. Ltd. assignee. Pyrimidine compound chloride salt thereof and manufacturing and application of same. US20200247797A1. 2023."},{"key":"e_1_3_4_84_1","unstructured":"Burch J Sun M Wang X et al. Inventor; Genentech Inc. assignee. Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds and Methods of Use. US20160213652A1. 2016."},{"key":"e_1_3_4_85_1","unstructured":"Chu-Biao X Yun-Long L Feng H et al. Inventor. Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors. KR20210110754A. 2022."},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.15430\/JCP.2018.23.3.109"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-323022"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0477-z"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.46"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1666.1666"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2365411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T12:28:29Z","timestamp":1727267309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2365411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,3]]}},"alternative-id":["10.1080\/13543776.2024.2365411"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2365411","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}